Article
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Cancer science - 1 Aug 2018
Azuma Koichi, Nishio Makoto, Hayashi Hidetoshi, Kiura Katsuyuki, Satouchi Miyako, Sugawara Shunichi, Hida Toyoaki, Iwamoto Yasuo, Inoue Akira, Takeda Koji, Ikeda Satoshi, Nakagawa Tomoki, Takeda Kentaro, Asahina Seitaro, Komatsu Kanji, Morita Satoshi, Fukuoka Masahiro, Nakagawa Kazuhiko
Abstract excerpt
Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.